Data from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients

Abstract

<div>Abstract<p><b>Purpose:</b> Tumor antigen–specific monoclonal antibodies (mAb) block oncogenic signaling and induce Fcγ receptor (FcγR)–mediated cytotoxicity. However, the role of CD8<sup>+</sup> CTL and FcγR in initiating innate and adaptive immune responses in mAb-treated human patients with cancer is still emerging.</p><p><b>Experimental Design:</b> FcγRIIIa codon 158 polymorphism was correlated with survival in 107 cetuximab-treated patients with head and neck cancer (HNC). Flow cytometry was carried out to quantify EGF receptor (EGFR)–specific T cells in cetuximab-treated patients with HNC. The effect of cetuximab on natural killer (NK) cell, dendritic cell (DC), and T-cell activation was measured using IFN-γ release assays and flow cytometry.</p><p><b>Results:</b> FcγRIIIa polymorphism did not predict clinical outcome in cetuximab-treated patients with HNC; however, elevated circulating EGFR<sub>853–861</sub>–specific CD8<sup>+</sup> T cells were found in cetuximab-treated patients with HNC (<i>P</i> < 0.005). Cetuximab promoted EGFR-specific cellular immunity through the interaction of EGFR<sup>+</sup> tumor cells and FcγRIIIa on NK cells but not on the polymorphism <i>per se</i>. Cetuximab-activated NK cells induced IFN-γ–dependent expression of DC maturation markers, antigen processing machinery components such as TAP-1/2 and T-helper cell (T<sub>H</sub>1) chemokines through NKG2D/MICA binding. Cetuximab initiated adaptive immune responses via NK cell–induced DC maturation, which enhanced cross-presentation to CTL specific for EGFR as well as another tumor antigen, MAGE-3.</p><p><b>Conclusion:</b> Cetuximab-activated NK cells promote DC maturation and CD8<sup>+</sup> T-cell priming, leading to tumor antigen spreading and T<sub>H</sub>1 cytokine release through “NK–DC cross-talk.” FcγRIIIa polymorphism did not predict clinical response to cetuximab but was necessary for NK–DC interaction and mAb-induced cross-presentation. EGFR-specific T cells in cetuximab-treated patients with HNC may contribute to clinical response. <i>Clin Cancer Res; 19(7); 1858–72. ©2013 AACR</i>.</p></div>